Tuesday, November 17, 2026

GET OUR FREE E-NEWSLETTER

“You may choose to look the other way, but you can never say again that you did not know.”

— William Wilberforce

Search

Controversial Hepatitis B Vaccine Birth Dose Trial in Guinea-Bissau Moves Forward

Controversial Hepatitis B Vaccine Birth Dose Trial in Guinea-Bissau Moves Forward

A proposed hepatitis B vaccine trial involving newborns in Guinea-Bissau is moving closer to implementation after the University of Southern Denmark approved a revised research protocol. The study, funded by the U.S. Centers for Disease Control and Prevention (CDC), has been faced criticism from international health organizations and pro-hepatitis B birth dose vaccination proponents in the U.S., who expressed concerns about ethical implications. Although the university and the relevant ethics committee in Guinea-Bissau have approved the revised protocol, the researchers still require final authorization from the country’s government before they can begin the trial.1 2

The research team at the University of Southern Denmark plans to recruit approximately 14,000 newborns and divide them into two groups. One group will receive the hepatitis B vaccine shortly after birth while the control group will follow Guinea-Bissau’s existing vaccination schedule, receiving its first dose at six weeks. Researchers aim to investigate whether administering the vaccine at birth affects other health outcomes, including childhood development, skin conditions and overall mortality.3

The proposed arrangement attracted criticism from the World Health Organization (WHO) and three Democratic members of the US House of Representatives. They questioned the decision to delay the first vaccine dose for some newborns until six weeks of age. The Democratic party politicians also highlighted the risks associated with hepatitis B infection during infancy, warning that up to nine in ten infected infants could develop a chronic infection, which can lead to liver failure or death.4

The researchers defended the study by referring to Guinea-Bissau’s existing vaccination schedule. Unlike countries that routinely administer the hepatitis B vaccine at birth, Guinea-Bissau currently provides the first dose at six weeks. In 2028, the country is scheduled to introduce a nationwide birth-dose program. Researchers argue that their proposed comparison reflects the country’s current “standard of care” vaccination rather than withholding a vaccine that newborns would otherwise routinely receive at birth.5

University Approves Revised Research Protocol

The controversy over “ethical” concerns resulted in a temporary suspension of the study while officials reviewed standard of care implications. A subsequent report by the University of Minnesota’s Center for Infectious Disease Research and Policy (CIDRAP) confirmed that the University of Southern Denmark had approved a revised version of the research protocol.6

Jakob Grauslund, MD, PhD,  dean of the University of Southern Denmark’s Faculty of Health Sciences, confirmed that he granted approval following an independent assessment by the university’s research ethics committee. The revised protocol had also received approval from the relevant ethics committee in Guinea-Bissau. However, the country’s government had not yet granted final authorization, meaning researchers could not begin the trial immediately.7

On the University of Southern Denmark’s Bandim Health Project’s website, the researchers state:

No child enrolled in the study will receive fewer vaccines than under current national policy in Guinea-Bissau. All children receive vaccines according to the routine vaccination schedule. Half receive an additional hepatitis B vaccine at birth that is not yet part of the national program. The study evaluates the introduction of a new policy; it does not remove an existing one.8

The website also explains that the revised design “includes maternal hepatitis B screening, immediate birth-dose vaccination for babies of mothers who test positive, a saline placebo, and a separate voluntary offer of HIV testing. In addition, our team will offer BCG, OPV and hepatitis B vaccines to all neonates whose mother declined to participate.”9

A Different Perspective on the Trial’s Ethics

In an article published on October 9, 2026, Vinay Prasad, MD, MPH discusses why he considers the proposed research ethically acceptable. He argues that the ethics of a clinical trial depend largely on the treatment participants in the comparison group receive, also known as the control group. In his opinion, participants should receive the standard medical care available in the country where the study takes place, while researchers test whether a new approach offers additional benefits.10

Dr. Prasad applies this reasoning to Guinea-Bissau, a country where the routine vaccination schedule gives babies their first hepatitis B vaccine dose at six weeks, rather than at birth. He argues that comparing health outcomes of this existing hepatitis B vaccine schedule at six weeks old with a birth dose schedule is ethically acceptable because the study does not deprive babies of a vaccine they would otherwise receive under the country’s current schedule. Instead, it tests whether adding a dose at birth improves health outcomes.11

He also points out that Guinea-Bissau plans is scheduled to introduce a nationwide birth-dose in 2028, meaning the trial could provide evidence of superior health outcomes with the birth dose schedule before that change takes place. Although he considers the study ethical and potentially useful, he acknowledges that study conclusions are uncertain. He says this uncertainty is precisely why researchers conduct randomized controlled trials, to establish whether an intervention provides a benefit, has no meaningful effect or causes harm.12


If you would like to receive an e-mail notice of the most recent articles published in The Vaccine Reaction each week, click here.

Click here to view References:

1 Szabo L. Hepatitis B vaccine study condemned as unethical wins approval from Danish university. The Center for Infectious Disease Research and Policy Oct. 8, 2026.
2 Parpia R. Guinea-Bissau Hepatitis B Vaccine Trial in Newborns Sparks Ethics Debate. The Vaccine Reaction Mar. 24, 2026.
3
4
5
6 Szabo L. Hepatitis B vaccine study condemned as unethical wins approval from Danish university. The Center for Infectious Disease Research and Policy Oct. 8, 2026.
7 Ibid.
8 Bandim Health Project. Ethical Questions about the Planned Hepatitis B Birth Dose trial in Guinea-Bissau.
9 Bandim Health Project. Revised hepatitis B birth-dose study receives ethical approval in Guinea-Bissau and Denmark but will not proceed.
10 Prasad, V. The ethics of a hepatitis B trial in the Guinea Bissau. Drvinayprasad.com Oct. 9, 2026.
11 Ibid.
12 Ibid.

Leave a Reply

Your email address will not be published. Required fields are marked *

Search in Archive

Search in Site

To search in site, type your keyword and hit enter

Search
The Vaccine Reaction
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.